Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALC Alcon	$84.77 -0.1%	$90.38	$80.48 ▼ $101.10	$41.87B	0.95	1.17 million shs	1.27 million shs
INO Inovio Pharmaceuticals	$1.95 +2.6%	$1.94	$1.42 ▼ $12.33	$69.68M	1.34	626,628 shs	560,050 shs
SNN Smith & Nephew SNATS	$28.53 -0.4%	$28.15	$23.69 ▼ $31.72	$12.54B	0.68	804,309 shs	890,947 shs
STE STERIS	$236.15 -0.4%	$233.97	$200.98 ▼ $252.79	$23.32B	0.94	548,329 shs	540,879 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALC Alcon	-0.08%	-4.34%	-5.11%	-7.23%	-5.10%
INO Inovio Pharmaceuticals	+2.63%	-8.02%	-5.80%	+0.52%	-77.22%
SNN Smith & Nephew SNATS	-0.25%	-5.34%	-1.94%	+0.19%	+13.42%
STE STERIS	-0.38%	-1.89%	-6.40%	+4.73%	+9.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALC Alcon	3.9642 of 5 stars	4.4	5.0	0.8	0.0	1.8	0.8	1.3
INO Inovio Pharmaceuticals	3.5941 of 5 stars	3.3	2.0	0.0	4.3	2.3	0.0	0.6
SNN Smith & Nephew SNATS	3.2942 of 5 stars	1.0	3.0	2.5	0.0	3.8	0.0	4.4
STE STERIS	4.8723 of 5 stars	3.3	5.0	3.3	3.8	2.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALC Alcon	2.80	Moderate Buy	$106.13	25.20% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	400.00% Upside
SNN Smith & Nephew SNATS	2.00	Hold	$28.00	-1.84% Downside
STE STERIS	2.63	Moderate Buy	$263.83	11.72% Upside

Current Analyst Ratings Breakdown

Latest STE, INO, SNN, and ALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	STE STERIS	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$263.00
5/22/2025	ALC Alcon	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/20/2025	ALC Alcon	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/19/2025	STE STERIS	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$240.00 ➝ $260.00
5/16/2025	STE STERIS	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/16/2025	STE STERIS	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$265.00 ➝ $280.00
5/15/2025	STE STERIS	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$250.00 ➝ $250.00
5/14/2025	ALC Alcon	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$102.00 ➝ $99.00
5/14/2025	ALC Alcon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $110.00
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALC Alcon	$9.91B	4.22	$5.55 per share	15.27	$43.70 per share	1.94
INO Inovio Pharmaceuticals	$220K	325.03	N/A	N/A	$1.90 per share	1.03
SNN Smith & Nephew SNATS	$5.81B	2.15	$3.14 per share	9.07	$12.04 per share	2.37
STE STERIS	$5.46B	4.26	$14.20 per share	16.63	$67.33 per share	3.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALC Alcon	$1.02B	$2.25	37.67	25.77	2.17	11.28%	6.95%	4.92%	8/19/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
SNN Smith & Nephew SNATS	$412M	$2.16	13.21	14.26	0.88	N/A	N/A	N/A	8/5/2025 (Estimated)
STE STERIS	$614.64M	$6.20	38.09	23.78	N/A	11.26%	14.21%	9.13%	8/5/2025 (Estimated)

Latest STE, INO, SNN, and ALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2025	STE STERIS	$2.59	$2.74	+$0.15	$1.47	$1.47 billion	$1.48 billion
5/13/2025	Q1 2025	ALC Alcon	$0.77	$0.73	-$0.04	$0.70	$2.52 billion	$2.33 billion
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALC Alcon	N/A	N/A	N/A	N/A	4 Years
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNN Smith & Nephew SNATS	$0.89	3.12%	N/A	41.20%	N/A
STE STERIS	$2.28	0.97%	N/A	36.77%	20 Years

Latest STE, INO, SNN, and ALC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/7/2025	STE STERIS	quarterly	$0.57	1.01%	6/10/2025	6/10/2025	6/26/2025
4/7/2025	ALC Alcon	annual	$0.3270	0.3%	5/14/2025	5/14/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALC Alcon	0.21	2.70	1.66
INO Inovio Pharmaceuticals	N/A	2.63	2.63
SNN Smith & Nephew SNATS	0.62	2.89	1.33
STE STERIS	0.29	1.96	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALC Alcon	53.86%
INO Inovio Pharmaceuticals	26.79%
SNN Smith & Nephew SNATS	25.64%
STE STERIS	94.69%

Insider Ownership

Company	Insider Ownership
ALC Alcon	1.52%
INO Inovio Pharmaceuticals	2.30%
SNN Smith & Nephew SNATS	1.00%
STE STERIS	1.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALC Alcon	25,599	493.24 million	485.75 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
SNN Smith & Nephew SNATS	17,349	437.96 million	433.58 million	Optionable
STE STERIS	17,787	98.37 million	97.32 million	Optionable

STE, INO, SNN, and ALC Headlines

Recent News About These Companies

Are Investors Undervaluing STERIS plc (NYSE:STE) By 40%?

June 18 at 3:38 PM | finance.yahoo.com

STERIS Stock: Is STE Outperforming the Healthcare Sector?

June 18 at 9:11 AM | finance.yahoo.com

STERIS plc (NYSE:STE) Shares Sold by Assenagon Asset Management S.A.

June 18 at 3:39 AM | marketbeat.com

STERIS plc (NYSE:STE) Shares Sold by Mn Services Vermogensbeheer B.V.

June 17 at 4:08 AM | marketbeat.com

STERIS plc (NYSE:STE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 17 at 1:48 AM | marketbeat.com

Vaughan Nelson Investment Management L.P. Raises Stake in STERIS plc (NYSE:STE)

June 16 at 4:24 AM | marketbeat.com

Zacks Research Brokers Lift Earnings Estimates for STERIS

June 16 at 1:55 AM | americanbankingnews.com

What is Zacks Research's Estimate for STERIS Q3 Earnings?

June 16 at 1:52 AM | marketbeat.com

STERIS plc (NYSE:STE) Shares Bought by Foster Victor Wealth Advisors LLC

June 15, 2025 | marketbeat.com

STERIS (NYSE:STE) Upgraded by Wall Street Zen to "Strong-Buy" Rating

June 15, 2025 | americanbankingnews.com

Ipswich Investment Management Co. Inc. Buys New Position in STERIS plc (NYSE:STE)

June 14, 2025 | marketbeat.com

STERIS (NYSE:STE) Stock Rating Upgraded by Wall Street Zen

June 14, 2025 | marketbeat.com

Why Is Steris (STE) Down 1.8% Since Last Earnings Report?

June 13, 2025 | zacks.com

SG Americas Securities LLC Boosts Stock Holdings in STERIS plc (NYSE:STE)

June 13, 2025 | marketbeat.com

STERIS plc (NYSE:STE) Stake Lowered by Handelsbanken Fonder AB

June 12, 2025 | marketbeat.com

Avanza Fonder AB Invests $2 Million in STERIS plc (NYSE:STE)

June 12, 2025 | marketbeat.com

Wedmont Private Capital Makes New Investment in STERIS plc (NYSE:STE)

June 12, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Steris (STE) and Apellis Pharmaceuticals (APLS)

June 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for STERIS Q1 Earnings

June 10, 2025 | americanbankingnews.com

STERIS plc (NYSE:STE) Shares Purchased by Fenimore Asset Management Inc

June 9, 2025 | marketbeat.com

Zacks Research Comments on STERIS's Q1 Earnings (NYSE:STE)

June 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks
By Gabriel Osorio-Mazilli | June 9, 2025
View Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks
Archer Aviation Stock Steadies After Short-Seller Report
By Jeffrey Neal Johnson | May 30, 2025
View Archer Aviation Stock Steadies After Short-Seller Report
After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
By Leo Miller | May 20, 2025
View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May
By Leo Miller | June 12, 2025
View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

STE, INO, SNN, and ALC Company Descriptions

Alcon NYSE:ALC

$84.77 -0.11 (-0.13%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$84.76 -0.01 (-0.01%)

As of 06/18/2025 06:27 PM Eastern

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Inovio Pharmaceuticals NASDAQ:INO

$1.95 +0.05 (+2.63%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.03%)

As of 06/18/2025 07:51 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Smith & Nephew SNATS NYSE:SNN

$28.52 -0.11 (-0.37%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$28.59 +0.06 (+0.22%)

As of 06/18/2025 05:03 PM Eastern

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

STERIS NYSE:STE

$236.15 -0.93 (-0.39%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$236.22 +0.07 (+0.03%)

As of 06/18/2025 04:39 PM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time